Abstract
The remarkable scientific progress in the treatment of patients with heart failure (HF) and reduced ejection fraction (HFrEF) has more than halved the risk of sudden cardiac death (SCD) in this setting. However, SCD remains one of the major causes of death in this patient population. Beyond the acknowledged role of beta blockers and inhibitors of the renin-angiotensin-aldosterone system (RAAS), a new class of drugs, the angiotensin receptor neprilysin inhibitors (ARNI), proved to reduce the overall cardiovascular mortality and, more specifically, the risk of SCD in HFrEF patients. The mechanism by which ARNI may reduce the mortality connected with harmful ventricular arrhythmias is not utterly clear. A variety of direct and indirect mechanisms have been suggested, but a favorable left ventricular reverse remodeling seems to play a key role in this setting. Furthermore, the well-known protective effect of implantable cardioverter-defibrillator (ICD) has been debated in HFrEF patients with non-ischemic cardiomyopathy (NICM) arguing against the role of primary prevention ICD in this setting, particularly when ARNI therapy is considered. The purpose of this review was to provide insights into the SCD mechanisms involved in HFrEF patients together with the current role of electrical therapies and new drug agents in this setting.
Similar content being viewed by others
References
Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF, Dargie HJ, Granger CB, Kjekshus J, Køber L, Latini R, Maggioni AP, Packer M, Pitt B, Solomon SD, Swedberg K, Tavazzi L, Wikstrand J, Zannad F, Zile MR, McMurray JJV (2017) Declining risk of sudden death in heart failure. N Engl J Med 377(1):41–51. https://doi.org/10.1056/NEJMoa1609758
Ponikowski P, Voors AA, Anker SD et al (2016) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 37(27):2129–2200m. https://doi.org/10.1093/eurheartj/ehw128
Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E, Jensen G, Hildebrandt P, Steffensen FH, Bruun NE, Eiskjær H, Brandes A, Thøgersen AM, Gustafsson F, Egstrup K, Videbæk R, Hassager C, Svendsen JH, Høfsten DE, Torp-Pedersen C, Pehrson S, DANISH Investigators (2016) Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 375(13):1221–1230. https://doi.org/10.1056/NEJMoa1608029
Desai AS, McMurray JJV, Packer M et al (2015) Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 36(30):1990–1997. https://doi.org/10.1093/eurheartj/ehv186
Al-Khatib SM, Stevenson WG, Ackerman MJ et al (2018) 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 138(13):e272–e391. https://doi.org/10.1161/CIR.0000000000000549
Solomon SD, Zelenkofske S, McMurray JJV, Finn PV, Velazquez E, Ertl G, Harsanyi A, Rouleau JL, Maggioni A, Kober L, White H, van de Werf F, Pieper K, Califf RM, Pfeffer MA, Valsartan in Acute Myocardial Infarction Trial (VALIANT) Investigators (2005) Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 352(25):2581–2588. https://doi.org/10.1056/NEJMoa043938
Zaman S, Kovoor P (2014) Sudden cardiac death early after myocardial infarction pathogenesis, risk stratification, and primary prevention. Circulation. 129(23):2426–2435. https://doi.org/10.1161/CIRCULATIONAHA.113.007497
Losurdo P, Stolfo D, Merlo M, Barbati G, Gobbo M, Gigli M, Ramani F, Pinamonti B, Zecchin M, Finocchiaro G, Mestroni L, Sinagra G (2016) Early arrhythmic events in idiopathic dilated cardiomyopathy. JACC Clin Electrophysiol 2(5):535–543. https://doi.org/10.1016/j.jacep.2016.05.002
Zecchin M, Merlo M, Pivetta A, Barbati G, Lutman C, Gregori D, Serdoz LV, Bardari S, Magnani S, di Lenarda A, Proclemer A, Sinagra G (2012) How can optimization of medical treatment avoid unnecessary implantable cardioverter-defibrillator implantations in patients with idiopathic dilated cardiomyopathy presenting with “sCD-HeFT Criteria?”. Am J Cardiol 109(5):729–735. https://doi.org/10.1016/j.amjcard.2011.10.033
Priori SG, Blomstrom-Lundqvist C, Mazzanti A et al (2015) ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the Europea. Eur Heart J 36(41):2793–2867l. https://doi.org/10.1093/eurheartj/ehv316
Hayashi M, Shimizu W, Albert CM (2015) The spectrum of epidemiology underlying sudden cardiac death. Circ Res 116(12):1887–1906. https://doi.org/10.1161/CIRCRESAHA.116.304521
Zhang D, Tu H, Wadman MC, Li YL (2018) Substrates and potential therapeutics of ventricular arrhythmias in heart failure. Eur J Pharmacol 833:349–356. https://doi.org/10.1016/j.ejphar.2018.06.024
Alvarez CK (2019) Heart failure as a substrate and trigger for ventricular tachycardia. J Interv Card Electrophysiol 56:229–247. https://doi.org/10.1007/s10840-019-00623-x
Nelson T, Garg P, Clayton RH, Lee J (2019) The role of cardiac MRI in the management of ventricular arrhythmias in ischaemic and non-ischaemic dilated cardiomyopathy. Arrhythmia Electrophysiol Rev 8(3):191–201. https://doi.org/10.15420/aer.2019.5.1
Disertori M, Rigoni M, Pace N, Casolo G, Masè M, Gonzini L, Lucci D, Nollo G, Ravelli F (2016) Myocardial fibrosis assessment by LGE is a powerful predictor of ventricular tachyarrhythmias in ischemic and nonischemic LV dysfunction: a meta-analysis. JACC Cardiovasc Imaging 9(9):1046–1055. https://doi.org/10.1016/j.jcmg.2016.01.033
Nakamori S, Dohi K, Ishida M, Goto Y, Imanaka-Yoshida K, Omori T, Goto I, Kumagai N, Fujimoto N, Ichikawa Y, Kitagawa K, Yamada N, Sakuma H, Ito M (2018) Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy. JACC Cardiovasc Imaging 11(1):48–59. https://doi.org/10.1016/j.jcmg.2017.04.006
Gorgels APM, Gijsbers C, De Vreede-Swagemakers J, Lousberg A, Wellens HJJ (2003) Out-of-hospital cardiac arrest - the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J 24(13):1204–1209. https://doi.org/10.1016/S0195-668X(03)00191-X
Halliday BP, Gulati A, Ali A, Guha K, Newsome S, Arzanauskaite M, Vassiliou VS, Lota A, Izgi C, Tayal U, Khalique Z, Stirrat C, Auger D, Pareek N, Ismail TF, Rosen SD, Vazir A, Alpendurada F, Gregson J, Frenneaux MP, Cowie MR, Cleland JGF, Cook SA, Pennell DJ, Prasad SK (2017) Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation. 135(22):2106–2115. https://doi.org/10.1161/CIRCULATIONAHA.116.026910
Peters S, Johnson R, Hershberger RE, Fatkin D (2019) Familial dilated cardiomyopathy. Hear Lung Circ:1–9. https://doi.org/10.1016/j.hlc.2019.11.018
Seferovic PM, Ponikowski P, Anker SD et al (2019) Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21:1169–1186. https://doi.org/10.1002/ejhf.1531
Moss AJ, Zareba W, Jackson Hall W et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346(12):877–883. https://doi.org/10.1056/NEJMoa013474
Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty S, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH, Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators (2005) Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med 352(3):225–237. https://doi.org/10.1056/NEJMoa043399
Bänsch D, Antz M, Boczor S et al (2002) Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT). Circulation. 105(12):1453–1458. https://doi.org/10.1161/01.CIR.0000012350.99718.AD
Strickberger SA, Hummel JD, Bartlett TG, Frumin HI, Schuger CD, Beau SL, Bitar C, Morady F, AMIOVIRT Investigators (2003) Amiodarone versus implantable cardioverter-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia - AMIOVIRT. J Am Coll Cardiol 41(10):1707–1712. https://doi.org/10.1016/S0735-1097(03)00297-3
Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, Sanders WE, Schaechter A, Levine JH, Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators (2004) Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 350(21):2151–2158. https://doi.org/10.1056/NEJMoa033088
Bristow MR, Saxon LA, Boehmer J et al (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350(21):2140–2150+2227. https://doi.org/10.1056/NEJMoa032423
Desai A, Fang JC, Maisel WH, Baughman KL (2004) Implantable defibrillators for the prevention. JAMA. 292(23):2874–2879
Romero J, Díaz JC, Grushko M et al (2018) Clinical impact of implantable cardioverter-defibrillator in primary prevention of total mortality in non-ischaemic cardiomyopathy: results from a meta-analysis of prospective randomized clinical trials. Europace 20(FI2):f211–f216. https://doi.org/10.1093/europace/eux324
Stavrakis S, Asad Z, Reynolds D (2017) Implantable cardioverter defibrillators for primary prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials. J Cardiovasc Electrophysiol 28(6):659–665. https://doi.org/10.1111/jce.13204
Haugaa KH, Tilz R, Boveda S, Dobreanu D, Sciaraffia E, Mansourati J, Papiashvili G, Dagres N (2017) Implantable cardioverter defibrillator use for primary prevention in ischaemic and non-ischaemic heart disease - indications in the post-DANISH trial era: results of the European Heart Rhythm Association survey. Europace. 19(4):660–664. https://doi.org/10.1093/europace/eux089
Schrage B, Uijl A, Benson L, Westermann D, Ståhlberg M, Stolfo D, Dahlström U, Linde C, Braunschweig F, Savarese G (2019) Association between use of primary-prevention implantable cardioverter-defibrillators and mortality in patients with heart failure. Circulation. 140(19):1530–1539. https://doi.org/10.1161/CIRCULATIONAHA.119.043012
Hjalmarson Å, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, el Allaf D, Vítovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, Jánosi A, Thorgeirsson G, Dunselman PHJM, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P, MERIT-HF Study Group (2000) Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. JAMA. 283(10):1295. https://doi.org/10.1001/jama.283.10.1295
Ruwald AC, Gislason GH, Vinther M et al (2018) Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study. Europace 20(FI2):f217–f224. https://doi.org/10.1093/europace/euy077
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348(14):1309–1321. https://doi.org/10.1056/NEJMoa030207
McMurray JJV, Packer M, Desai AS et al (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371(11):993–1004. https://doi.org/10.1056/NEJMoa1409077
Xie W, Zheng F, Song X, Zhong B, Yan L (2016) Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: network meta-analysis. Int J Cardiol 205(2016):65–71. https://doi.org/10.1016/j.ijcard.2015.12.010
Hubers SA, Brown NJ (2016) Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation. 133(11):1115–1124. https://doi.org/10.1161/CIRCULATIONAHA.115.018622
Iborra-Egea O, Gálvez-Montón C, Roura S et al (2017) Mechanisms of action of sacubitril/valsartan on cardiac remodeling: a systems biology approach. Npj Syst Biol Appl 3(1):1–8. https://doi.org/10.1038/s41540-017-0013-4
Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE (2011) Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging 4(1):98–108. https://doi.org/10.1016/j.jcmg.2010.10.008
Kong MH, Fonarow GC, Peterson ED, Curtis AB, Hernandez AF, Sanders GD, Thomas KL, Hayes DL, al-Khatib SM (2011) Systematic review of the incidence of sudden cardiac death in the United States. J Am Coll Cardiol 57(7):794–801. https://doi.org/10.1016/j.jacc.2010.09.064
Zile MR, Claggett BL, Prescott MF, McMurray JJV, Packer M, Rouleau JL, Swedberg K, Desai AS, Gong J, Shi VC, Solomon SD (2016) Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol 68(22):2425–2436. https://doi.org/10.1016/j.jacc.2016.09.931
Daubert MA, Adams K, Yow E, Barnhart HX, Douglas PS, Rimmer S, Norris C, Cooper L, Leifer E, Desvigne-Nickens P, Anstrom K, Fiuzat M, Ezekowitz J, Mark DB, O’Connor CM, Januzzi J, Felker GM (2019) NT-proBNP goal achievement is associated with significant reverse remodeling and improved clinical outcomes in HFrEF. JACC Heart Fail 7(2):158–168. https://doi.org/10.1016/j.jchf.2018.10.014
Weiner RB, Baggish AL, Chen-Tournoux A, Marshall JE, Gaggin HK, Bhardwaj A, Mohammed AA, Rehman SU, Barajas L, Barajas J, Gregory SA, Moore SA, Semigran MJ, Januzzi JL Jr (2013) Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur J Heart Fail 15(3):342–351. https://doi.org/10.1093/eurjhf/hfs180
Martens P, Beliën H, Dupont M, Vandervoort P, Mullens W (2018) The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther 36(4):1–7. https://doi.org/10.1111/1755-5922.12435
Januzzi JL, Prescott MF, Butler J et al (2019) Association of change in n-terminal pro-b-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 322:1085–1095. https://doi.org/10.1001/jama.2019.12821
Desai AS, Solomon SD, Shah AM et al (2019) Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA - Journal of the American Medical Association 322:1077–1084. https://doi.org/10.1001/jama.2019.12843
Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D (2019) Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis. J Am Heart Assoc 8(13). https://doi.org/10.1161/JAHA.119.012272
Kang DH, Park SJ, Shin SH, Hong GR, Lee S, Kim MS, Yun SC, Song JM, Park SW, Kim JJ (2019) Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation: PRIME study. Circulation. 139(11):1354–1365. https://doi.org/10.1161/CIRCULATIONAHA.118.037077
Nishimura S, Kawai Y, Nakajima T et al (2006) Membrane potential of rat ventricular myocytes responds to axial stretch in phase, amplitude and speed-dependent manners. Cardiovasc Res 72(3):403–411. https://doi.org/10.1016/j.cardiores.2006.08.011
Trayanova NA, Constantino J, Gurev V (2010) Models of stretch-activated ventricular arrhythmias. J Electrocardiol 43:479–485. https://doi.org/10.1016/j.jelectrocard.2010.05.014 Elsevier Inc.
Chang PC, Lin SF, Chu Y, Wo HT, Lee HL, Huang YC, Wen MS, Chou CC (2019) LCZ696 therapy reduces ventricular tachyarrhythmia inducibility in a myocardial infarction-induced heart failure rat model. Cardiovasc Ther 2019:1–9. https://doi.org/10.1155/2019/6032631
de Diego C, González-Torres L, Núñez JM, Centurión Inda R, Martin-Langerwerf DA, Sangio AD, Chochowski P, Casasnovas P, Blazquéz JC, Almendral J (2018) Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices. Heart Rhythm 15(3):395–402. https://doi.org/10.1016/j.hrthm.2017.11.012
Martens P, Nuyens D, Rivero M et al (2019) Sacubitril / valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction. Clin Res Cardiol 108(10):1074–1082. https://doi.org/10.1007/s00392-019-01440-y
Sutherland GR (2017) Sudden cardiac death: the pro-arrhythmic interaction of an acute loading with an underlying substrate. Eur Heart J 38(40):2986–2994. https://doi.org/10.1093/eurheartj/ehw449
Levine YC, Rosenberg MA, Mittleman M, Samuel M, Methachittiphan N, Link M, Josephson ME, Buxton AE (2014) B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias. Heart Rhythm 11(7):1109–1116. https://doi.org/10.1016/j.hrthm.2014.04.024
Seegers J, Bergau L, Expósito PM, Bauer A, Fischer TH, Lüthje L, Hasenfuß G, Friede T, Zabel M (2016) Prediction of appropriate shocks using 24-hour Holter variables and T-wave alternans after first implantable cardioverter-defibrillator implantation in patients with ischemic or nonischemic cardiomyopathy. Am J Cardiol 118:86–94. https://doi.org/10.1016/j.amjcard.2016.04.016 The Authors
Banasik G, Segiet O, Elwart M, Szulik M, Lenarczyk R, Kalarus Z, Kukulski T (2016) LV mechanische Dispersion als Prädiktor ventrikulärer Arrhythmie bei Patienten mit fortgeschrittener systolischer Herzinsuffizienz: Eine Pilotstudie. Herz. 41(7):599–604. https://doi.org/10.1007/s00059-015-4398-9
Haugaa KH, Grenne BL, Eek CH, Ersbøll M, Valeur N, Svendsen JH, Florian A, Sjøli B, Brunvand H, Køber L, Voigt JU, Desmet W, Smiseth OA, Edvardsen T (2013) Strain echocardiography improves risk prediction of ventricular arrhythmias after myocardial infarction. JACC Cardiovasc Imaging 6(8):841–850. https://doi.org/10.1016/j.jcmg.2013.03.005
Valentim Gonçalves A, Pereira-da-Silva T, Galrinho A, Rio P, Moura Branco L, Soares R, Feliciano J, Ilhão Moreira R, Cruz Ferreira R (2019) Antiarrhythmic effect of sacubitril-valsartan: cause or consequence of clinical improvement? J Clin Med 8(6):869. https://doi.org/10.3390/jcm8060869
Wang Z, Taylor LK, Denney WD, Hansen DE (1994) Initiation of ventricular extrasystoles by myocardial stretch in chronically dilated and failing canine left ventricle. Circulation 90(4 I):2022–2031. https://doi.org/10.1161/01.CIR.90.4.2022
El-Battrawy I, Pilsinger C, Liebe V et al (2019) Impact of sacubitril/valsartan on the long-term incidence of ventricular arrhythmias in chronic heart failure patients. J Clin Med 8(10):1582. https://doi.org/10.3390/jcm8101582
Author information
Authors and Affiliations
Contributions
All authors read and approved the final manuscript.
• Study conception and design: Drs. Andrea Lorenzo Vecchi, Jacopo Marazzato
• Literature search and data analysis: Drs. Andrea Lorenzo Vecchi, Raffaele Abete, Jacopo Marazzato
• Drafting of manuscript: Drs. Andrea Lorenzo Vecchi, Raffaele Abete, Jacopo Marazzato, Attilio Iacovoni
• Critical revision: Prof. Roberto De Ponti, Prof. Andrea Mortara, Prof. Michele Senni
Corresponding author
Ethics declarations
Conflict of interest
Drs. Andrea Lorenzo Vecchi, Raffaele Abete, Jacopo Marazzato, Attilio Iacovoni, and Roberto De Ponti declare that they have no conflicts of interest or financial ties to disclose.
Dr. Michele Senni declares financial interest for consultancy with Novartis, Merck, Bayer, Vifor Pharma, Abbott, Boehringer Ingelheim, AstraZeneca, Bioventrix, and Servier.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Vecchi, A.L., Abete, R., Marazzato, J. et al. Ventricular arrhythmias and ARNI: is it time to reappraise their management in the light of new evidence?. Heart Fail Rev 27, 103–110 (2022). https://doi.org/10.1007/s10741-020-09991-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10741-020-09991-3